Consistent with our in vitro results, targeted metabolomics analysis of tumor lysates revealed that SIRT5 silencing resulted in a significant downregulation in the levels of R5P and nucleotides (Fig. 7g). The gene discussed is SIRT5; the disease is neoplasm.